Re:Cognition Health Launches Trial for Blood-Based Alzheimer's Diagnosis
Re:Cognition Health is conducting an international clinical trial to evaluate a finger-prick blood test for early Alzheimer's diagnosis. This method aims to replace current invasive and costly diagnostic techniques. The trial will involve 1,000 participants from the UK, US, and Canada, including diverse groups to address research gaps. The study will analyze blood samples for proteins linked to Alzheimer's, comparing results with traditional methods like PET scans and MRIs. This initiative could lead to earlier and more accessible diagnosis, crucial for effective treatment. 
